Harvard CFAR Twitter Feed
- Dolutegravir-Based Strategies Offer Benefits for Women With HIV t.co/rQSEibiBNp
- According to a @NIH-funded clinical trial, 86% of people who received #HIV care soon after diagnosis maintained viral suppression after 48 weeks: t.co/9AZcgbT352
- #DYK: #CDCYRBS data can be used to identify resources that help prevent #HIV among youth? t.co/QHeaA5Flpd t.co/zMYZmAmXS8
- Two-thirds of people who could benefit most from #PrEP are African-American or Latino, but they account for the lowest percentage of PrEP prescriptions. Learn more about PrEP and #HIV: t.co/ckNiRBmCc5 t.co/PKDgXyKfSl
The mission of the HU CFAR is to expand, promote and facilitate collaborative innovative multidisciplinary activities in HIV/AIDS research in order to bring an end to the epidemic.